Unlearn.AI, a machine learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, announced that Eisai, a research and development-based pharmaceutical company, has joined the company’s syndicate of investors as part of its Series A extension along with Epic Ventures and Alumni Ventures Group.
In April 2020, Unlearn announced Series A financing led by 8VC with participation from DCVC, DCVC Bio, and Mubadala Capital Ventures. The extension brings the Series A total to $15 million.
Unlearn has also announced its flagship product, Digital Twins for Alzheimer’s Disease. Unlearn has developed a proprietary AI-model used to generate Digital Twins that are statistically indistinguishable from actual Alzheimer’s Disease patient data. Study sponsors can incorporate a cohort of Digital Twins matched to all of the patients in a given trial to populate Intelligent Control Arms. Intelligent Control Arms can be added prospectively, enabling smaller, more efficient trials, or retrospectively, adding power to trials already enrolling. Unlearn Digital Twins for Alzheimer’s Disease are already being used as part of an ongoing, pivotal trial.
“Unlearn has proven how generative AI-models trained on clinical data can be successfully utilized to create Digital Twins of patients for complex populations such as Alzheimer’s Disease. We believe that the Unlearn technology and its Intelligent Control Arms have the potential to solve the enrollment challenges, timeline delays, and high failure rates that too often burden clinical trials,” said Shun Asami, Ph.D., Senior Director, Eisai Innovation.
“We are pleased to collaborate with Unlearn to help advance Eisai’s mission to find precision solutions that go beyond treatment, to prevention and potential reversal of devastating neurological conditions such as Alzheimer’s Disease.”
Image Credit: Unlearn.AI